Vor Biopharma

Vor Biopharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vor Biopharma (VOR) as of Oct 18, 2026 is -371.64 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -121.19 M USD — a change of 206.67% (lower).

EBITDA

-371.64 MUSD

YoY

206.67%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vor Biopharma is 2025 -371.64 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vor Biopharma was 2024 -121.19 M USD. It decreases by 206.67% lower compared to the previous year.

The Vor Biopharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-2.86 M USD
Jan 1, 2019
-10.39 M USD
Jan 1, 2020
-43.37 M USD
Jan 1, 2021
-69.02 M USD
Jan 1, 2022
-93.42 M USD
Jan 1, 2023
-126.04 M USD
Jan 1, 2024
-121.19 M USD
Jan 1, 2025
-371.64 M USD
The Vor Biopharma EBITDA history
YEAREBITDAYoY
-371.64 MUSD+206.67%
-121.19 MUSD-3.85%
-126.04 MUSD+34.92%
-93.42 MUSD+35.35%
-69.02 MUSD+59.15%
-43.37 MUSD+317.58%
-10.39 MUSD+263.11%
-2.86 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vor Biopharma Stock analysis

What does Vor Biopharma do? Vor Biopharma Inc, headquartered in Cambridge, Massachusetts, develops cell therapies for cancer treatment, focusing on hematological malignancies. The company employs 76 full-time staff and is listed on the stock market since February 5, 2021. Its lead product, tremtelectogene empogeditemcel (trem-cel), targets acute myeloid leukemia and other blood cancers using a proprietary platform that genetically modifies hematopoietic stem cells to eliminate cancer cell surface targets. The company is advancing clinical trials for its lead candidate in AML treatment. Vor Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vor Biopharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vor Biopharma is -371.64 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vor Biopharma changed from -121.19 M USD to -371.64 M USD, representing a 206.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Vor Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Vor Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Vor Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Vor Biopharma